store at low temperature,keep away from direct sunlight
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Z-VAD-FMK (Caspase Inhibitor VI) is a broad-spectrum inhibitor of caspases with irreversible properties. Z-VAD-FMK binds to activated caspases, thereby inhibiting apoptosis.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 121.00 | |
5 mg | In stock | $ 257.00 | |
10 mg | In stock | $ 438.00 | |
25 mg | In stock | $ 696.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 283.00 |
Description | Z-VAD-FMK (Caspase Inhibitor VI) is a broad-spectrum inhibitor of caspases with irreversible properties. Z-VAD-FMK binds to activated caspases, thereby inhibiting apoptosis. |
In vitro |
METHODS: Neutrophils were treated with Z-VAD-FMK (0.03-300 µM) for 30 min, then incubated with 200 U/mL TNFα for 6 h. Apoptosis was detected by Flow Cytometry. RESULTS: Z-VAD-FMK had a biphasic effect on TNFα-stimulated neutrophil apoptosis. 100 µM or more of Z-VAD-FMK enhanced TNFα-induced apoptosis, whereas 30 µM or less inhibited apoptosis. [1] METHODS: Human colorectal cancer cells HCT116 and SW480 were pretreated with Z-VAD-FMK (20 μM) for 1 h, then incubated with CPT (10-1000 ng/mL) and 5-FU (5-12.5 μg/mL) for 48 h to induce apoptosis, and then the expression levels of target proteins were detected by Western Blot. RESULTS: CPT and 5-FU induced significant up-regulation of cleaved caspase-3, caspase-8 and PARP, and Z-VAD-FMK pretreatment eliminated the activation of apoptosis-related proteins. [2] METHODS: Human T-lymphoblastic leukemia cells Jurkat were treated with Z-VAD-FMK (10-200 µM) for 24 h after pulsing, and cell viability was measured using propidium iodide. RESULTS: The optimal concentration of Z-VAD-FMK was 50 µM, which increased cell viability from 35% to 74% compared to untreated control. [3] |
In vivo |
METHODS: To detect anti-tumor activity in vivo, C57/BL6 mice bearing mouse melanoma tumor B16 were treated with RT (2 Gy local irradiation of the tumor on day 8/9/10), DTIC (2 mg/pc intraperitoneal injection on day 8/10), and a combination of Z-VAD-FMK (2 mg/kg intraperitoneal injection on day 8/9/10) and HT (4 h post-irradiation on day 8/10). RESULTS: Multimodal tumor therapy with RT, DTIC, and HT in combination with Z-VAD-FMK retarded tumor growth in a T-cell-dependent manner. [4] METHODS: To investigate the role of Z-VAD-FMK in endotoxin shock, Z-VAD-FMK (5-20 μg/g) was administered as a single intraperitoneal injection to LPS-induced endotoxin shock in C57BL/6 mice. RESULTS: Z-VAD-FMK treatment significantly prolonged the survival time of mice for several hours and increased the survival rate. Z-VAD-FMK treatment significantly reduced the mortality rate of mice treated with different doses of LPS. [5] |
Synonyms | Z-VAD(OH)-FMK, Caspase Inhibitor VI, Z-VAD |
Molecular Weight | 453.46 |
Formula | C21H28FN3O7 |
CAS No. | 161401-82-7 |
store at low temperature,keep away from direct sunlight
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: < 1 mg/mL (insoluble or slightly soluble)
Ethanol: 83 mg/mL (183 mM)
DMSO: 83 mg/mL (183 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Z-VAD-FMK 161401-82-7 Apoptosis Proteases/Proteasome Caspase inhibit Inhibitor ZVADFMK Hela Z VAD FMK Antiapoptosis cells pan-caspase Z-VAD(OH)-FMK Caspase Inhibitor VI Z-VAD inhibitor